Antisense Oligonucleotide Reverses Leukodystrophy in Canavan Disease Mice

Area of Science:

• Neuroscience
• Genetics
• Biochemistry

Background:

• Canavan disease is a rare genetic leukodystrophy characterized by elevated brain N-acetyl-L-aspartate (NAA).
• This condition results from a deficiency in the enzyme aspartoacylase, which normally cleaves NAA in oligodendrocytes.

Purpose of the Study:

• To investigate the therapeutic potential of inhibiting NAA synthesis in a mouse model of Canavan disease.
• To determine if targeting NAA production can reverse neurological deficits and neuropathological changes.

Main Methods:

• Utilized a mouse model with aspartoacylase deficiency, mimicking Canavan disease.
• Administered a locked nucleic acid antisense oligonucleotide intracisternally to inhibit NAA synthesis.
• Assessed neurological function (ataxia) and performed histological analysis of brain tissue.

Main Results:

• Intracisternal administration of the antisense oligonucleotide reversed pre-existing ataxia in affected mice.
• Significant reduction in cerebellar and thalamic vacuolation was observed.
• Diminished Purkinje cell dendritic atrophy was noted in treated mice.

Conclusions:

• Inhibiting NAA synthesis is a viable therapeutic strategy for Canavan disease.
• This approach can reverse established neurological symptoms and neuropathology.
• Targeting NAA production offers a promising avenue for treating this leukodystrophy.